Goldman Sachs: SKB BIO (06990) sac-TMT combined therapy clinical research reaches main endpoint, maintains "buy" rating.

Goldman Sachs released a research report, raising the SKB BIO (06990) 2027 and 2028 earnings per share forecasts to 7.51 RMB and 14.46 RMB, respectively. The target price was raised from 561.4 Hong Kong dollars to 582.95 Hong Kong dollars, maintaining a "buy" rating and believing that Kollonborgtai is expected to become an influential global ADC drug company. Kollonborgtai announced the antibody-drug conjugate (ADC) targeting trophoblastic cell surface antigen 2 (TROP2) Luconashatuzumab duocarmycin (sac-TMT, also known as SKB264/MK-2870), in combination with Merck's anti-PD-1 antibody "Keytruda," for first-line treatment of locally advanced or metastatic NSCLC with negative PD-L1 phase 3 clinical trial (OptiTROP-Lung06) has reached the primary endpoint. The bank expects that the positive results of the clinical study will be a key step in the treatment of 1L NSCLC, raising the success rate of Lung06 from 81% to 90%. The success rate for overseas 1L NSCLC PD-L1 tumors with proportion scores (TPS) <50% has increased from 54% to 63%.